Immunology / Virology & Vaccines

#Covid-19 #Immunology / Virology & Vaccines #Public health #Sinovac #Vaccines

Has China approved a Covid-19 vaccine for three year olds?

The New York Times has reported that the Chairman of the Chinese drug maker Sinovac said China had approved the company’s Covid-19 vaccine for children as young as three, which the media outlet explains would make the country the first in the world to endorse a vaccine for children of… Read More

#Covid-19 #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines #Pfizer #Vaccine candidate

Can Pfizer-BioNTech vaccine target the Delta variant?

Levels of antibodies in the blood of vaccinated people that can recognise and fight the new SARS-CoV-2 Delta variant first discovered in India (B.1.617.2) are on average lower than those against previously circulating variants in the UK, according to new laboratory data from the Francis Crick Institute and the National… Read More

#Covid-19 #News #Trending News

#Covid-19 #Drug development #Immunology / Virology & Vaccines

Is a needle-free Covid-19 vaccination possible?

University of Queensland scientists have successfully protected mice from the Covid-19 virus by administering a US-developed vaccine candidate with a ‘patch’, rather than a needle. The University of Texas Hexapro vaccine candidate, delivered via the UQ-developed and Vaxxas-commercialised high-density microarray patch (HD-MAP), provided protection against Covid-19 disease with a single,… Read More

#Covid-19 #News #Trending News

#Anti-viral drug screening #Assay validation #Automated workflows #Drug screening #High throughput screening #Immunology / Virology & Vaccines #Microplate readers #SARS-CoV-2

Webinar: Improving work rate, productivity and getting to market faster

We know there are operational vulnerabilities in pharmaceutical research and in the drug discovery pipeline. Bringing new drugs to the market is slow and expensive, with high costs, failure rates and cycle times. With low reproducibility and inefficient processes delaying the path to approval, the current pandemic is prompting a… Read More

#News

#Clinical trial #Clinical Trial Authorisation #Covid-19 #Immunology / Virology & Vaccines #Moderna #mRNA

Moderna initiates rolling submission of Biologics License Application (BLA)

Moderna has initiated the rolling submission process with the U.S. Food and Drug Administration for a Biologics License Application (BLA) for the licensure of its mRNA COVID-19 Vaccine to prevent COVID-19 in individuals 18 years of age and older. Stéphane Bancel, Chief Executive Officer of Moderna, said: “We look forward… Read More

#News #Trending News

#Drug delivery #Drug development #Immunology / Virology & Vaccines #mRNA #Vaccines

Samsung Biologics adds mRNA vaccine manufacturing to its services

Samsung Biologics, a CDMO, plans to add mRNA vaccine drug substance (DS) manufacturing capability to its current facility in Songdo, ready for cGMP operations within early 2022. mRNA has been the technology of choice for many Covid-19 vaccines due to its characteristics of safety and fast scalability in manufacturing. “We… Read More

#News

#Clinical trial #Covid-19 #Immunology / Virology & Vaccines #Moderna

Moderna Covid-19 vaccine safe and effective in teens

Moderna has announced that its Phase II/III study of its Covid-19 vaccine (mRNA-1273) in adolescents has met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination. In the study, no cases of Covid-19 were observed in participants who had received two doses of the Moderna Covid-19… Read More

#Covid-19 #News #Trending News

#Clinical trials #Covid-19 #Drug delivery #Drug development #Immunology / Virology & Vaccines #Johnson & Johnson #Vaccines

Janssen single-dose COVID-19 vaccine approved for use in the UK

Johnson & Johnson has announced topline efficacy and safety data from the Phase III ENSEMBLE clinical trial, demonstrating that the investigational single-dose Covid-19 vaccine in development at Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468… Read More

#Covid-19 #News #Trending News

#Epidemiology #Immunology / Virology & Vaccines #Pfizer

Pfizer launches Vaccine Centre of Excellence

Pfizer has launched a Centre of Excellence for Epidemiology of Vaccine-preventable Diseases at the University of Bristol. The centre, which is the second to launch to date and the first outside the US, will be led by Adam Finn, Professor of Paediatrics at Bristol, Director of the Bristol Vaccine Centre… Read More

#News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Royal visit to celebrate key role in vaccine development

Malvern Panalytical, experts in high-precision analytical instruments, welcomed His Royal Highness The Earl of Wessex, Prince Edward, to its Worcestershire headquarters. Malvern Panalytical was selected for the Royal visit, amongst a small number of other Worcestershire businesses, primarily because of its scientific and technical contribution to the development of medicines… Read More

#News #Trending News

#Biotechnology #Diagnostics #Drug discovery #Immunology #Immunology / Virology & Vaccines #Pandemic

University of Oxford to launch Pandemic Sciences Centre

The University of Oxford has announced the launch of a new centre of global research collaboration and excellence, the Pandemic Sciences Centre. Its mission will be to ensure that the world is better equipped to create global, and equitable science-driven solutions to prepare for, identify, and counter future pandemic threats. Read More

#News #Trending News

#Clinical research #Clinical trial #Covid-19 #Immunology / Virology & Vaccines #Vaccines

Positive interim Phase II results for GSK Medicago Covid-19 vaccine

Medicago and GlaxoSmithKline (GSK) have reported positive interim Phase II clinical trial safety and immunogenicity data for Medicago’s plant-derived Covid-19 vaccine candidate, which has been tested in combination with GSK’s pandemic adjuvant. These results are part of the ongoing Phase II/III study and reiterate the promising profile observed during Phase… Read More

#Covid-19 #News

Patient receiving vaccine
#Clinical trials #Covid-19 #Immunology / Virology & Vaccines #Vaccines

Sanofi and GSK Covid-19 vaccine to progress to Phase III trials

The Sanofi and GSK adjuvanted recombinant Covid-19 vaccine candidate achieved strong rates of neutralising antibody responses, in line with those measured in people who have recovered from Covid-19, in all adult age groups in a Phase II study with 722 volunteers. The Phase II interim results showed 95% to 100%… Read More

#Covid-19 #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines #mRNA #Vaccines

CureVac GSK Covid-19 vaccine candidate shows high immunogenicity

CureVac, in collaboration with GSK, has announced that its second-generation Covid-19 vaccine candidate, CV2CoV, induces high levels of antigen production as well as strong and dose-dependent immune responses in vaccinated animals. CV2CoV is a co-development between CureVac and GSK and is based on a new mRNA backbone, which differs from… Read More

#Covid-19 #News

#Anti-viral drug screening #Assay validation #Automated workflows #Drug screening #High throughput screening #Immunology / Virology & Vaccines #Microplate readers #SARS-CoV-2

How to improve work rate, productivity and get to market faster

Research laboratories have not fundamentally changed since the 1960s, says BMG LABTECH. Despite improvements in technology such as high-throughput screening and computational drug design, drug discovery is becoming slower and more expensive over time. Covid-19 highlighted operational vulnerabilities which are driving a fundamental reassessment of strategic priorities. In fact, says… Read More

#Editor's Choice #News